This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yan, W. Articles by Chen, X. Search for Related Content PubMed PubMed Citation Articles by Yan, W. Articles by Chen, X.

Targeted Repression of Bone Morphogenetic Protein 7, a Novel Target of the p53 Family, Triggers Proliferative Defect in p53-Deficient Breast Cancer Cells

Center for Comparative Oncology, University of California at Davis, Davis, California

Requests for reprints: Xinbin Chen, Center for Comparative Oncology, University of California at Davis, 2128 Tupper Hall, Davis, CA 95616. Phone: 530-754-8404; Fax: 530-752-6042; E-mail: xbchen{at}ucdavis.edu.

p53 tumor suppressor and its family members, p63 and p73, are known to play a role in the survival of cells exposed to stress signals. As a transcription factor, the p53 family proteins induce a plethora of target genes that mediate their functions in the cell cycle, apoptosis, and other biological activities. However, the mechanism by which the p53 family proteins regulate their cell survival functions is still not clear. Here, we showed that bone morphogenetic protein 7 (BMP7) is a novel target gene regulated by the p53 family and mediates the cell survival function of the basal physiologically relevant level of p53. Specifically, we found that knockdown of BMP7 markedly inhibits the proliferation of p53-deficient, but not p21-knockdown, breast cancer cells compared with the ones with wild-type p53. In addition, we found that inhibitor of differentiation or DNA binding 2 (Id2), a transcription factor implicated for cell survival, is regulated by the BMP7 and p53 pathways. Interestingly, whereas a functional BMP7 or p53 pathway is sufficient to maintain the basal level of Id2 expression, loss of both pathways abrogates Id2 expression. Furthermore, we showed that overexpression of Id2 can restore p53-deficient cells to survive in the absence of BMP7. As a result, we identified a previously unrecognized role for BMP7 in the maintenance of cell survival for p53-deficient cells, at least in part, through Id2. Together, we hypothesize that breast cancer patients with mutant p53 might benefit from targeted repression of BMP7 expression and/or targeted inhibition of the BMP7 pathway. [Cancer Res 2007;67(19):9117–24]

This article has been cited by other articles:

				Y. Choi and C. Kendziorski Statistical methods for gene set co-expression analysis Bioinformatics, November 1, 2009; 25(21): 2780 - 2786. [Abstract] [Full Text] [PDF]

				L. De Rosa, D. Antonini, G. Ferone, M. T. Russo, P. B. Yu, R. Han, and C. Missero p63 Suppresses Non-epidermal Lineage Markers in a Bone Morphogenetic Protein-dependent Manner via Repression of Smad7 J. Biol. Chem., October 30, 2009; 284(44): 30574 - 30582. [Abstract] [Full Text] [PDF]

				W. Yan and X. Chen Identification of GRO1 as a Critical Determinant for Mutant p53 Gain of Function J. Biol. Chem., May 1, 2009; 284(18): 12178 - 12187. [Abstract] [Full Text] [PDF]

				Y. Zhang, L. Shu, and X. Chen Syntaxin 6, a Regulator of the Protein Trafficking Machinery and a Target of the p53 Family, Is Required for Cell Adhesion and Survival J. Biol. Chem., November 7, 2008; 283(45): 30689 - 30698. [Abstract] [Full Text] [PDF]

				W. Yan, G. Liu, A. Scoumanne, and X. Chen Suppression of Inhibitor of Differentiation 2, a Target of Mutant p53, Is Required for Gain-of-Function Mutations Cancer Res., August 15, 2008; 68(16): 6789 - 6796. [Abstract] [Full Text] [PDF]